在人卵母细胞体外成熟过程中补充FGF2、LIF和IGF1(FLI)可增强配子胜任力标志物
该研究纳入2018年1月至2021年12月间接受卵巢组织冷冻保存的75例儿童、青少年和年轻成人,将卵巢组织处理过程中回收的卵丘-卵母细胞复合体(COC)和裸卵在标准成熟液或补充FLI(FGF2 40 ng/ml、LIF 20 ng/ml、IGF1 20 ng/ml)的成熟液中行体外成熟42小时。FLI未提高减数分裂成熟率,但显著增加卵丘细胞扩展、MAPK表达并增强跨带突起回缩。
要点
- FLI补充未增加人IVM的减数分裂成熟率(COC:对照组25.0% vs FLI组28.6%中期II阻滞卵)。
- FLI组卵丘细胞扩展较对照组增加1.9倍,跨带突起回缩更明显(16小时:对照组2.45±0.50 vs FLI组1.16±0.78个突起)。
- FLI成熟16-18小时的COC卵丘细胞MAPK表达显著升高(化学发光校正面积对照组621,678 vs FLI组2,019,575 a.u.,P=0.03)。
核心结论
- FLI补充未增加人IVM中卵母细胞减数分裂成熟的发生率,但显著改善了质量结局,包括卵丘细胞扩展增加、MAPK表达升高以及跨带突起回缩增强。
- 作者认为FLI补充可能对儿童、青少年和年轻成人的IVM具有保守的有益效应,跨越农业环境至临床生育力保存。
研究设计与样本
- 研究纳入2018年1月至2021年12月在芝加哥Ann & Robert H. Lurie儿童医院生育与激素保存及恢复项目接受临床生育力保存的75例参与者。
- 参与者捐献卵巢组织处理过程中累积的OTC培养基用于研究,纳入人群包括≤22岁的儿童、青少年和年轻成人。
- 所有参与者的COC和裸卵从卵巢组织处理后的培养基中回收,随后在标准成熟液或补充FLI(FGF2 40 ng/ml、LIF 20 ng/ml、IGF1 20 ng/ml)的成熟液中行IVM。
- IVM结局包括减数分裂进程、卵丘细胞扩展、跨带突起回缩和MAPK蛋白表达检测。
主要发现
- 参与者中位年龄6.3岁,65%按Tanner分期为青春期前,约60%在OTC前接受过化疗和/或放疗。
- 平均每例参与者从OTC培养基中回收4.7±1个COC和/或裸卵;COC(N=41)和裸卵(N=29)用于标准或FLI补充成熟液行IVM(42小时)。
- 减数分裂成熟发生率在两组间相似:COC为对照组25.0% vs FLI组28.6%中期II阻滞卵;裸卵为对照组0% vs FLI组5.3%。
- FLI组COC的卵丘细胞扩展较对照组增加1.9倍,跨带突起回缩更明显(16小时:对照组2.45±0.50 vs FLI组1.16±0.78个突起)。
- FLI成熟16-18小时的COC卵丘细胞MAPK表达显著更高(化学发光校正面积对照组621,678 vs FLI组2,019,575 a.u.,P=0.03)。
局限性
- 样本来自人类参与者,在年龄、诊断和既往治疗史方面存在异质性。
- 需要未来更大样本量、包含成人参与者的研究来确定FLI诱导MAPK表达和激活的机制。
- 在临床转化之前,需要评估FLI处理所获卵母细胞发育能力的研究,包括以胚胎为结局指标的评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does a chemically defined maturation medium supplemented with FGF2, LIF, and IGF1 (FLI) improve in vitro maturation (IVM) of cumulus-oocyte complexes (COCs) obtained from children, adolescents, and young adults undergoing ovarian tissue cryopreservation (OTC)? SUMMARY ANSWER: Although FLI supplementation did not increase the incidence of oocyte meiotic maturation during human IVM, it significantly improved quality outcomes, including increased cumulus cell expansion and mitogen-activated protein kinase (MAPK) expression as well as enhanced transzonal projection retraction. WHAT IS KNOWN ALREADY: During OTC, COCs, and denuded oocytes from small antral follicles are released into the processing media. Recovery and IVM of these COCs is emerging as a complementary technique to maximize the fertility preservation potential of the tissue. However, the success of IVM is low, especially in the pediatric population. Supplementation of IVM medium with FLI quadruples the efficiency of pig production through improved oocyte maturation, but whether a similar benefit occurs in humans has not been investigated. STUDY DESIGN, SIZE, DURATION: This study enrolled 75 participants between January 2018 and December 2021 undergoing clinical fertility preservation through the Fertility & Hormone Preservation & Restoration Program at the Ann & Robert H. Lurie Children's Hospital of Chicago. Participants donated OTC media, accumulated during tissue processing, for research. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants who underwent OTC and include a pediatric population that encompassed children, adolescents, and young adults ≤22 years old. All participant COCs and denuded oocytes were recovered from media following ovarian tissue processing. IVM was then performed in either a standard medium (oocyte maturation medium) or one supplemented with FLI (FGF2; 40 ng/ml, LIF; 20 ng/ml, and IGF1; 20 ng/ml). IVM outcomes included meiotic progression, cumulus cell expansion, transzonal projection retraction, and detection of MAPK protein expression. MAIN RESULTS AND THE ROLE OF CHANCE: The median age of participants was 6.3 years, with 65% of them classified as prepubertal by Tanner staging. Approximately 60% of participants had been exposed to chemotherapy and/or radiation prior to OTC. On average 4.7 ± 1 COCs and/or denuded oocytes per participant were recovered from the OTC media. COCs (N = 41) and denuded oocytes (N = 29) were used for IVM (42 h) in a standard or FLI-supplemented maturation medium. The incidence of meiotic maturation was similar between cohorts (COCs: 25.0% vs 28.6% metaphase II arrested eggs in Control vs FLI; denuded oocytes: 0% vs 5.3% in Control vs FLI). However, cumulus cell expansion was 1.9-fold greater in COCs matured in FLI-containing medium relative to Controls and transzonal projection retraction was more pronounced (2.45 ± 0.50 vs 1.16 ± 0.78 projections in Control vs FLIat 16 h). Additionally, MAPK expression was significantly higher in cumulus cells obtained from COCs matured in FLI medium for 16-18 h (chemiluminescence corrected area 621,678 vs 2,019,575 a.u., P = 0.03). LIMITATIONS, REASONS FOR CAUTION: Our samples are from human participants who exhibited heterogeneity with respect to age, diagnosis, and previous treatment history. Future studies with larger sample sizes, including adult participants, are warranted to determine the mechanism by which FLI induces MAPK expression and activation. Moreover, studies that evaluate the developmental competence of eggs derived from FLI treatment, including assessment of embryos as outcome measures, will be required prior to clinical translation. WIDER IMPLICATIONS OF THE FINDINGS: FLI supplementation may have a conserved beneficial effect on IVM for children, adolescents, and young adults spanning the agricultural setting to clinical fertility preservation. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by Department of Obstetrics and Gynecology startup funds (F.E.D.), Department of Surgery Faculty Practice Plan Grant and the Fertility & Hormone Preservation & Restoration Program at the Ann & Robert H. Lurie Children's Hospital of Chicago (M.M.L. and E.E.R.). M.M.L. is a Gesualdo Foundation Research Scholar. Y.Y.'s research is supported by the internal research funds provided by Colorado Center of Reproductive Medicine. Y.Y., L.D.S., R.M.R., and R.S.P. have a patent pending for FLI. The remaining authors have no conflict of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Amargant F, Zhou LT, Yuan Y, et al. FGF2, LIF, and IGF1 (FLI) supplementation during human in vitro maturation enhances markers of gamete competence. Hum Reprod. 2023. PMID: 37608600. doi:10.1093/humrep/dead162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。